drugset / Trial / NCT05205005

Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

NCT05205005 ↗

Phase 2/3 Completed 24 enrolled VA Office of Research and Development
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The prevalence of type 2 diabetes (T2D) continues to increase in the US, with 26.8 million adults carrying a diagnosis. Importantly, T2D is widespread in the Veteran population. This epidemic of T2D also contributes to the staggering rates of cardiovascular disease and cardiovascular mortality. Lifestyle modifications, including increased physical activity, are recommended as first-line therapy for the management of T2D. Unfortunately, patients with T2D exhibit diminished vascular adaptations to exercise. The proposed project will test the overall hypothesis that degradation of the endothelial glycocalyx, a characteristic feature of T2D, precludes shear stress mechanotransduction and consequent exercise-induced vascular adaptations. As such, the investigators pose that restoration of the endothelial glycocalyx via dietary supplementation of glycocalyx precursors will potentiate vascular adaptations to exercise in Veterans with T2D.

Timeline

Start
2022-05-25
Primary completion
2024-03-31
Completion
2024-07-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Endocalyx Other / unclassified 3712 mg —